Achievement and maintenance of viral suppression in persons newly diagnosed with HIV, New York City, 2006-2009: Using population surveillance data to measure the treatment part of "test and Treat"

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 3, 2013, Pages 379-386

  Torian, Lucia V ^a,b   Xia, Qiang ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b Department of Health and Mental Hygiene in the HIV   (United States)

Author keywords

HIV viral load; New York city; Newly diagnosed HIV; Viral suppression

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HAZARD RATIO; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT RESPONSE; UNITED STATES; VIRAL PHENOMENA AND FUNCTIONS; VIRAL SUPPRESSION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; NEW YORK CITY; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; RNA, VIRAL; UNITED STATES; YOUNG ADULT;

EID: 84880192635     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182926b02     Document Type: Article

References (31)

1. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
2. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
3. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397-1404.
4. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
5. Fideli US, Allen SA, Musonda R, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses. 2001;17:901-910.
6. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PloS One. 2010;5:e11068.
7. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
8. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS. 2010;24:729-735.
9. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.
10. Wagner BG, Blower S. Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs. PloS One. 2012;7:e41212.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2011: 1-161.
12. Jia Z, Ruan Y, Li Q, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet 2012 [epub ahead of print; doi: 10.1016/S0140-6736(12)61898-4].
13. Folkers GK, Fauci AS. Controlling and ultimately ending the HIV/AIDS pandemic: a feasible goal. JAMA. 2010;304:350-351.
14. Fairchild AL, Bayer R. HIV surveillance, public health, and clinical medicine-will the walls come tumbling down? N Engl J Med. 2011; 365:685-687.
15. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296:1498-1506.
16. Do T, Duncan J, Butcher A, et al. Comparative frequencies of HIV low-level viremia between real-time viral load assays at clinically relevant thresholds. J Clin Virol. 2011;52(suppl 1):S83-S89.
17. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adoles-cents. Washington, DC: Department of Health and Human Services; 2007.
18. Torian LV, Wiewel EW, Liu KL, et al. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med. 2008;168:1181-1187.
19. State of New York Laws. HIV Testing and Counseling. Amendment to New York State Public Health Law Article 21, Amendment of Part 63 of Title 10, Codes, Rules and Regulations of the State of New York (HIV/AIDS Testing, Reporting and Confidentiality of HIV-Related Information). Chapter 308. Albany, NY: State of New York; 2010.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2012.
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services; 2006.
22. Giordano TP, Gifford AL, White AC Jr, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44:1493-1499.
23. Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care. 2005;43(suppl 9):III40-52.
24. Meyerson BE, Klinkenberg WD, Perkins DR, et al. Who's in and who's out: use of primary medical care among people living with HIV. Am J Public Health. 2007;97:744-749.
25. New York City Department of Health and Mental Hygiene. HIV epidemiology and field services surveillance slide sets. New York, NY: 2012. Available at: http://www.nyc.gov/html/doh/html/data/epi-surveillance. shtml. Accessed February 26, 2013.
26. The White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Washington, DC, 2010.
27. Torian LV, Wiewel EW. Continuity of HIV-related medical care, New York City, 2005-2009: do patients who initiate care stay in care? AIDS Patient Care STDs. 2011;25:79-88.
28. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793-800.
29. Andrews JR, Wood R, Bekker LG, et al. Projecting the benefits of anti-retroviral therapy for HIV prevention: the impact of population mobility and linkage to care. J Infect Dis. 2012;206:543-551.
30. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis. 2010;51:725-731.
31. Eavey JJ, Torian LV, Jablonsky A, et al. Undiagnosed HIV infection in a New York City emergency room. Presented at: XIX International AIDS Conference; July 22-27, 2012; Washington, DC. Abstract #TUPE282.